Search Results
Your search for ASCO matches 21351 pages
Showing 18851 - 18900ASCO Names Advance of the Year, Reviews Top Research Trends
In just a year’s time, four new therapies have been approved for patients with chronic lymphocytic leukemia (CLL), treatments that are highly effective and far easier for patients to tolerate. These therapies are a major step forward, bringing renewed hope to nearly 120,000 people living with CLL...
Five Organizations Awarded 2015 International Innovation Grants to Improve Cancer Care in Low- and Middle-Income Countries
The Conquer Cancer Foundation of ASCO has announced the five recipients of the 2015 International Innovation Grant. This grant supports novel and innovative projects that may improve diagnosis, prevention, and treatment of cancer in low- and middle-income countries. For 2015, the 1-year grants of...
Cornerstone Spotlight: Frank M. Muller, Jr
Frank M. Muller, Jr, the newest member of the Conquer Cancer Foundation (CCF) Cornerstone Planned Giving Society, has a 40-year history of successfully leading investment and high-tech corporations. He served 8 years on active duty in tours to Vietnam. It is rare for him to experience a challenge...
Molecular Classification Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer
Radical cystectomy is the standard therapeutic option for patients with muscle-invasive bladder cancer. However, 5-year overall survival for high-risk patients with pT3, pT4, pN-negative, and pN-positive M0 bladder cancer after radical cystectomy is only about 50% and ranges from 32% in patients...
University of Pittsburgh Appoints Director of Stem Cell Transplantation
Warren Shlomchik, MD, has been named Director of Stem Cell Transplantation and Cell Therapies for the University of Pittsburgh’s Division of Hematology-Oncology and the University of Pittsburgh Cancer Institute (UPCI). His appointment is effective March 1, 2015. He also will serve as UPCI’s...
Treating Bladder Cancer in 2015
Treatment of advanced bladder cancer continues to prove challenging, and therapies that offer long-term survival remain elusive. The ASCO Post recently spoke with Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, President of the Levine Cancer Center, Charlotte, North Carolina, about the current state...
FDA Appoints Robert Califf, MD, Deputy Commissioner for Medical Products and Tobacco
U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, MD, has appointed Robert Califf, MD, as the FDA Deputy Commissioner for Medical Products and Tobacco. Dr. Califf is a leader in cardiology, clinical research, and medical economics, who is currently serving as Vice...
FDA Expands Approved Use of Ibrutinib for Waldenström’s Macroglobulinemia
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for patients with Waldenström’s macroglobulinemia, a rare, indolent type of B-cell lymphoma. Ibrutinib is the first therapy indicated specifically for Waldenström’s macroglobulinemia and previously...
Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy: A Winner in Older Patients With Leukemia
Inotuzumab ozogamicin combined with a low-intensity chemotherapy called mini-hyper-CVD achieved highly encouraging results in older patients with acute lymphoblastic leukemia (ALL) in a phase II study reported at the 56th Annual Meeting of the American Society of Hematology.1 After the...
Expert Point of View: Ann H. Partridge, MD, MPH
Ann H. Partridge, MD, MPH, Associate Professor of Medicine at Harvard Medical School, commented on this study to The ASCO Post: With taxanes after doxorubicin/cyclophosphamide (AC), it’s “dealer’s choice.” However, she noted that most oncologists do not give every-3-week paclitaxel now. “Many have...
ASCO Releases Annual Report on Progress Against Cancer
ASCO recently released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). The report credited improvements in CLL care with four...
Cancer Genetics: Looking Back, Looking Ahead
At the 2014 San Antonio Breast Cancer Symposium, The ASCO Post sat down with geneticist Mary-Claire King, PhD, for some personal musings about her career and how she might guide young researchers who want to follow in her footsteps. Dr. King is known for a variety of accomplishments in genetics,...
Expert Point of View: George J. Chang, MD
George J. Chang, MD, Chief of Colon and Rectal Surgery and Director of Clinical Operations, Minimally Invasive and New Technologies in Oncologic Surgery Program at The University of Texas MD Anderson Cancer Center, Houston, shared his insights on the study by Dr. Smith and colleagues with The ASCO...
Dr. Howard Fine Named Founding Director of the Brain Tumor Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Howard A. Fine, MD, has been appointed to lead the newly established neuro-oncology program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, effective February 2. He will serve as Director of the Brain Tumor Center and Associate Director for Translational Research in the Sandra and...
Glioblastoma Clinical Trials
I am writing in regard to the recent installment to “Clinical Trials” on Glioblastoma published in The ASCO Post (February 10, 2015, pages 69-71). As a principal investigator, I’d also like to call attention to the following glioblastoma trial, which remains open. PHASE II Study Type: Phase...
More on Beating the Odds
Thank you very much for including Mr. Richard Heimler’s very rewarding story in The ASCO Post (“Beating the Odds,” December 1, 2014, page 118). It was a short, well-written example of excellent oncology management in the face of episodes of “terminal” lung cancer. His story was the perfect...
ASCO to Launch Journal of Global Oncology, Names Founding Editor-in-Chief
ASCO has announced the appointment of David Kerr, MD, DSc, as founding Editor-in-Chief of the Society’s new Journal of Global Oncology (JGO). Dr. Kerr will set the editorial scope and vision for JGO, an online-only, open-access journal, which will focus on cancer care, research, and care-delivery...
Expect Questions About Atypical Hyperplasia as an Important Risk Factor for Breast Cancer
A special report in The New England Journal of Medicine concluded that atypical hyperplasia of the breast “confers an absolute risk of later breast cancer of 30% at 25 years of follow-up.1” This is higher than previously recognized, and the report’s authors urged “more intensive screening and...
Atypical Hyperplasia as a Predictor of Future Breast Cancer: Focus on Chemoprevention and Screening
Atypical hyperplasia of the breast has “special importance as a predictor of future breast cancer,” according to a special report in The New England Journal of Medicine.1 That special importance is based on the high incidence of atypical hyperplasia—found in around 10% of the 1 million breast...
Physician-Scientist Guido Marcucci, MD, Joins City of Hope
Renowned physician and researcher Guido Marcucci, MD, has joined City of Hope in a key leadership role within the institution’s new Hematologic Malignancies and Stem Cell Transplantation Institute. As Director of the Gehr Family Center for Leukemia Research and as Chief of the Division of...
Thomas J. Smith, MD, Honored by the American Cancer Society
Thomas J. Smith, MD, has been selected by the American Cancer Society to be the recipient of the 2015 Trish Greene Quality of Life Award. This award honors the life and work of the late Patricia (Trish) Greene, RN, PhD. As progress in the detection and treatment of cancer prolonged lives and...
Roswell Park Cancer Institute Announces Candace S. Johnson, PhD, as 15th President and Chief Executive Officer
The Roswell Park Cancer Institute (RPCI) Board of Directors has named Candace S. Johnson, PhD, as the Institute’s 15th President and Chief Executive Officer (CEO). Dr. Johnson will be the first female leader for this 117-year-old comprehensive cancer center. “Over the past few months, we have met...
NCI-Funded Program on Screening for Psychosocial Distress Accepting Applications
Funded by a grant from the National Cancer Institute (NCI), the Screening for Psychosocial Distress Program is a joint project of Yale University School of Nursing and the American Psychosocial Oncology Society (APOS). The Screening for Psychosocial Distress Program trains cancer care providers on...
Susan M. O’Brien Joins UC Irvine/Chao Family Comprehensive Cancer Center
Susan M. O’Brien, MD has joined UC Irvine Health as Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research. A renowned researcher and clinician, Dr. O’Brien’s leadership...
2015 Oncology Meetings
FEBRUARY Genitourinary Cancers SymposiumFebruary 26-28 • Orlando, Florida For more information: www.gucasym.org 5th Annual Texas Adolescent and Young Adult Oncology ConferenceFebruary 27-28 • Houston, Texas For more information:...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Skull Sarcoma Removed Under Local Anesthesia, East Prussia, Circa 1921
The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The Radium Era: 1916–1945.” To view additional photos from this series...
At Long Last: CMS Will Cover Lung Cancer Screening
Few issues in health-care debates are more contentious and polarizing than population screening for the early detection of cancer. After a decades-long battle, lung cancer screening advocates have just received what they have long sought: The Centers for Medicare & Medicaid Services (CMS) has...
ASTRO Announces Additions to Management Team
The American Society for Radiation Oncology’s (ASTRO) Board of Directors has announced three additions to the Society’s management team: Emily Wilson has been named Executive Vice President; Dave Adler has been promoted to Vice President of Advocacy; and Anne Hubbard has been promoted to Director...
Capsaicin
Scientific name: 8-methyl-N-vanillyl-6-nonenamide Brand names: Zostrix cream 0.025% or 0.075%, Salonpas Gel-Patch Hot, Sinus Buster (homeopathic intranasal spray). The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence ...
Blinatumomab in Philadelphia Chromosome–Negative Relapsed/Refractory B-Cell Precursor ALL
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 3, 2014, blinatumomab (Blincyto) was granted...
Iniparib: The Fairy Tale Dream Comes to an End
The first poly ADP ribose polymerase (PARP) inhibitor was developed in the early 1990s. Since then, the activity of PARP inhibitors has been explored in a variety of settings, including and perhaps most enthusiastically in the treatment of cancer. The greater dependence of several cancers on PARP,...
Ibrutinib for Waldenström’s Macroglobulinemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 29, 2015, the U.S. Food and Drug Administration (FDA)...
Case Reports on Myeloid Neoplasm
Case 1: Prerequisites for classification of myeloid neoplasm Question 1: Which statement is the one best explanation for the discrepancy observed between the blast percentage by bone marrow aspirate visual inspection and the flow-cytometry study? Correct Answer: C. Flow-cytometry study may not be...
Two Case Reports on the Evaluation of Myeloid Neoplasm
The ASCO Post is pleased to introduce “Hematology Expert Review,” a new feature including a case report detailing a particular hematologic condition followed by questions. Answers to each question appear with expert commentary. In this first installment, we present two cases of older men with...
IOM Report Recommends Guidelines for Sharing Clinical Trial Data
A new report from the Institute of Medicine (IOM) provides recommended guidelines about what data should be shared at key times in a clinical trial. In its report, Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk, an IOM committee concludes that sharing data is in the public...
Show Your Patients the Latest Research on Genitourinary Cancers
The 2015 Genitourinary Cancers Symposium takes place February 26 to 28 in Orlando, Florida. Direct your patients to www.cancer.net/blog to read about the latest research on prostate, bladder, kidney, testicular, and other genitourinary cancers being presented at the meeting. ■ © 2015. American...
Health-Care Issues Front and Center on Capitol Hill, in Statehouses This Year
As of January 6, Republicans hold the majority in both houses of the 114th Congress. They hold 54 seats in the U.S. Senate and 245 seats in the U.S. House of Representatives. At the state level, Republicans now hold an increased majority of governorships and legislatures that will consider numerous ...
Funding Promising Women Researchers: Women Who Conquer Cancer
Tomorrow’s cancer breakthroughs depend on making sure that talented young researchers have the chance to succeed today. Providing early funding for women in clinical oncology research is the singular goal of Women Who Conquer Cancer, a meaningful program of the ASCO-affiliated Conquer Cancer...
ASCO, AACR Call for Regulation of Electronic Nicotine Delivery Systems
ASCO and the American Association for Cancer Research (AACR) released a joint statement in January to guide policymakers as they work to minimize the potential negative consequences of electronic cigarettes (e-cigarettes) and other electronic nicotine delivery systems. Tobacco use, according to the ...
Conquer Cancer Foundation Researchers Lead Six Key Studies Featured in Clinical Cancer Advances 2015
Six of the studies featured in the recently released Clinical Cancer Advances 2015: ASCO’s Annual Report on Progress Against Cancer were led by researchers that whom Conquer Cancer Foundation (CCF) funded early in their careers through its signature Young Investigator Award (YIA) and Career...
Molecular Oncology Tumor Boards Invite Discussion of Growing Field in Cancer Care
Oncologists and other related health-care providers now have an online platform for the discussion of the growing area of tumor molecular profiling tests and studies. In January, ASCO launched the Molecular Oncology Tumor Boards, a series of monthly user-driven discussions designed to help...
How Changes to ACGME’s Accreditation Standards Are Affecting Fellowship Training
Two years ago, the Accreditation Council for Graduate Medical Education (ACGME), the nonprofit organization that evaluates and accredits more than 9,000 medical residency programs in the United States, began phasing in implementation of its Next Accreditation System for graduate medical education,...
ASCO Endorsement of ESMO Guidelines on Hereditary Colorectal Cancer Syndromes
In a recent issue of the Journal of Clinical Oncology,1 and as reviewed in this issue of The ASCO Post, an ASCO expert endorsement panel reviewed and endorsed, with minor qualifications, the European Society for Medical Oncology (ESMO) clinical practice guidelines for management of familial/genetic ...
ASCO Endorses ESMO Guideline on Hereditary Colorectal Cancer Syndromes
Approximately 5% to 6% of cases of colorectal cancer are associated with germline mutations conferring an inherited predisposition for disease. As reported by Stoffel and colleagues in the Journal of Clinical Oncology,1 ASCO has endorsed, with qualifying statements, the European Society for Medical ...
Expert Point of View: George Sledge, MD
Discussion of the TNT trial was brisk at the 2014 San Antonio Breast Cancer Symposium. George Sledge, MD, Professor of Medicine and Chief of Oncology at Stanford University School of Medicine, Palo Alto, California, called the study “intriguing” and commented: “The platinum results, I believe, are...
CMS Issues Final Decision to Cover Lung CT Screening
Earlier this month the Centers for Medicare & Medicaid Services (CMS) issued a final national coverage determination that provides for Medicare coverage of screening for lung cancer with low-dose computed tomography (LDCT). Effective immediately, Medicare will now cover lung cancer screening...
International Society of Geriatric Oncology: At the Forefront of Physician Education and Research Dissemination in Geriatric Oncology
The ASCO Post announces a new department on geriatric oncology to be published on an occasional basis. Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on...
FOLFIRINOX Plus Radiation Renders Some Locally Advanced Pancreatic Cancer Patients Resectable
Investigators from Moffitt Cancer Center in Tampa, Florida, have reported an approach to pancreatic cancer that downstages some locally advanced patients to borderline resectable status and achieves a negative surgical margin rate exceeding 96%. The study earned a Merit Award at the 2015...
Surgery Plus Immunotherapy Improves Survival in Melanoma Patients With Gastrointestinal Metastases
When melanoma patients develop metastases to the gastrointestinal (GI) tract or pancreas, resection of these lesions may improve survival, according to two single-institution studies presented at the 2015 Gastrointestinal Cancers Symposium. In a study that earned a Merit Award, researchers reported ...
